Speakers
Confirmed speakers as of February 27, 2009
Find the Panels & Workshops Program here
 | Alim Louis Benabid Professor Emeritus at "Joseph Fourier" University, Grenoble, France PANEL 2 :The brain device interface | Alim Louis Benabid has centred his scientific activity on the approach of neurosurgical pathologies, particularly brain tumours and movement disorders, namely Parkinson's disease. He developed in his hospital robotic stereotactic surgery which permits biopsies and therapeutics acts, aimed at functional targets (...) |
.jpg) | Fernand Badano Chief Operating Officer, Valtronic Technologies, France PANEL 2 :The brain device interface | Fernand BADANO, 46, PhD, is the Chief Operating Officer of Valtronic Technologies, an international group active in contract development and manufacturing of medical devices, and General Manager of MedTech (...) |
| Dr Simon Burnell Head of Diagnostics, Cambridge Consultants WORKSHOP5 Theranostics | Simon works at Cambridge Consultants as a Commercial Director and leads the diagnostics group in the Medical Technology Division. This group contains the senior client and project managers of Cambridge Consultants healthcare business covering the areas of |
 | Maria Livanos Cattaui Member of the Board of Directors, Petroplus Holdings AG OPENING PLENARY SESSION | Maria Livanos Cattaui was Secretary General of ICC from July 1996 to June 2005. She has championed the role of world business in the global economy. She has been instrumental in establishing a global partnership between business and the United Nations, leading to greater business input into UN economic activities. |
 | Jean Chabbal CEA: head of the technologies for healthcare division WORKSHOP4: New trends in Nanomedicine. What's new in miniaturizing? | Jean Chabbal has been with CEA Leti for over five years as head of the technologies for healthcare division. He has extensive experience in developing and manufacturing detectors and equipments for imaging and medical applications (...) |
.jpg) | Marc Cluzel, M.D., Ph.D. Senior Vice President, Research & Development sanofi-aventis OPENING PLENARY SESSION | Medical Doctor, Pneumologist and Ph.D. in Biochemistry, after a 6-year hospital medical activity, Marc Cluzel worked as a Visiting Assistant Professor in Medicine, at the Johns Hopkins University from 1987 to 1990, and as a Research Associate at the London Guy’s Hospital, from 1990 to 1991. |
 | Daniel Cohen, CEO Pharnext PANEL1: More R&D investment but no more drugs approved. What's wrong? | Professor Daniel Cohen (Chairman) MD, PhD. Professor in Genetic Medicine, founder of CEPH, Généthon, Millenium, a former CSO at Genset and VP Worldwide Genetics at Serono (...) |
.jpg)  | Steven Conlan Co-Director, Centre for NanoHealth WORKSHOP4: New trends in Nanomedicine. What's new in miniaturizing? | Steve Conlan is a Senior Lecturer in Cell and Molecular Biology in the Reproductive Biology Group at the School of Medicine, Swansea University, where he also leads the School’s activities in NanoHealth (...) |
.jpg) | Marc Essodaigui Vice President Marketing & Sales, Europe & Asia - Ipsogen WORKSHOP5:Theranostics | Marc Essodaigui studied biology, chemistry and physics at Pierre and Marie Curie University, Paris, where he obtained a Ph.D. in molecular biophysics in 1998 (...) |
 | Jonas Garding Doctor Of Research and Physics, Elekta, Sweden PANEL 2 :The brain device interface | Jonas Gårding (Ph.D.) is the Director of Research and Physics at Elekta Instrument AB in Stockholm, Sweden. He received his Ph.D. degree Computer Science and Image Analysis in 1991 from Royal Institute of Technology (KTH), Stockholm (...) |
 | Corey Goodman, Ph.D. President, Biotherapeutics and Bioinnovation Center,Pfizer PANEL1: More R&D investment but no more drugs approved. What's wrong? | Corey Goodman is the President of Pfizer’s Biotherapeutics and Bioinnovation Center. Corey joined Pfizer to head this newly established entrepreneurial R&D division to combine cutting-edge biology, advanced biologic technologies, and an entrepreneurial biotech-like culture to discover and develop new biotherapeutics. |
 | Willy De Greef Secretary General of EuropaBio, EU WORKSHOP1:Overview of the public financial supports of biotech | Willy De Greef is a plant biologist with extensive experience in tropical crop breeding (through research management positions in the Democratic Republic of Congo, Malawi and Cameroon) and in technology transfer related to agricultural biotechnology (....) |
| Patrice Courvalin, Professor and head of the Antibacterial Agents Unit, National Reference Center for Antibiotics, Institut Pasteur WORKSHOP2 New Antibiotherapies for tomorrow |
|
 | Abdelkader Guellil Founder and CEO Akaeno WORKSHOP3:The Cleantech Market in Europe | Founder and CEO of Akaeno, Abdelkader Guellil holds a PhD in Water Chemistry and Microbiology. He began his professional career in the research center of a major company in the environmental services sector (...) |
| Timothy Hall DG Research, European Commission OPENING PLENARY SESSION | Timothy Hall, T.J. Hall worked as an agricultural research scientist in the UK before joining the European Commission services in 1983, becoming Head of Unit for S&T Cooperation with Developing Countries in 1994. He has also headed units in the Quality of Life and Health Research Directorates between 1999 and 2006. (...) |
.jpg) |
Prof. Dr. Peter Hammann Global infectious disease initiative, co-leader, sanofi aventis WORKSHOP2: New Antibiotherapies for tomorrow | Peter Hammann obtained an engineering degree in Biochemistry form the TU Darmstadt, his doctorate in chemistry he received from the TU Hannover and his habilitation was accepted by the Veterinary University of Hannover in Organic Chemistry, where he also is serving as adjunct Professor. |
 | Frédéric Hammel CEO Txcell WORKSHOP 6: Cellular therapies, challenging but promising | Fred Hammel is the CEO of TxCell, a biotechnology company dedicated to the development of new therapeutic treatments for auto- immune diseases. Fred has more than 15 years of experience in life science innovations (...) |
 | Jeff Hillman Chief Scientific Officer, ONI BioPharma, Inc WORKSHOP2: New Antibiotherapies for tomorrow | Dr. Hillman holds numerous U.S. and foreign patents for inventions and discoveries that cover a wide range of health-related research, including tooth decay and periodontal (gum) diseases, antibiotics, cancer (...) |
 | François Houssin Senior Development Manager, European Listing, NYSE Euronext, France WORKSHOP3:The Cleantech Market in Europe | François is responsible for the commercial development of the Listing activity in France at NYSE Euronext, the world’s first stock exchange, by supporting companies on their way to listing on the stock market (...) |
 | Alain Huriez Chairman and Chief Executive Officer of TcLand Expression SA. WORKSHOP5:Theranostics | Alain Huriez MD, 45, married 4 children, is since mid 2006 Chairman and Chief Executive Officer of TcLand Expression SA. Alain is one the company’s co-founders.(...) |
|
| Tim Joslin, Defined Health’s Managing Director, Europe WORKSHOP2: New Antibiotherapies for tomorrow | Tim is Defined Health’s “on the ground” point of contact for our European clients. He is responsible for developing business and managing clients from the European branch office of Defined Health, located in Basel, Switzerland (...) |
 | Albin JOURDA Managing Director, GALLIUM MOORE WORKSHOP3:The Cleantech Market in Europe | Albin is Managing Director with Gallium Moore, an independent financial advisory firm providing support on fund raising, M&A and partnerships. Albin has more than 10 years of experience in IT, biotech and cleantech innovation. |
 | Alan Klein Executive Vice-President, Corporate Development, Sequella WORKSHOP2: New Antibiotherapies for tomorrow | Having worked in the Pharmaceutical/Biotech sector for 19 years, Mr. Klein has held a variety of leadership positions focused on the growth and management of corporations and individual business units. |
 | Dr. Roger Kravtzoff Preclinical and clinical development director Flamel Technologies. WORKSHOP4: New trends in Nanomedicine. What's new in miniaturizing? | After Dr Roger Kravtzoff received his Ph.D in Biochemistry at the Pharmacy School, Tours University (France), he worked at Biophor Corporation, Texas (USA) and the Regional Blood Center, Tours (France) as Research Engineer leading research on drug delivery systems. (...) |
 | Ludo Lauwers, M.D. Senior Vice President, Beerse R&D Site Manager at Johnson & Johnson Pharmaceuticals PANEL1: More R&D investment but no more drugs approved. What's wrong? | Ludo Lauwers, M.D. is Senior Vice President, Beerse R&D Site Manager at Johnson & Johnson Pharmaceuticals and chairs the Beerse R&D Senior Leadership Team. He is member of the CNS-IM R&D Board. He is Vice-Chairman of the Management Board of Janssen Pharmaceutica NV and Chairman of the Board of Janssen-Cilag International NV. |
 | Laurent Levy CEO Nanobiotix, France WORKSHOP4: New trends in Nanomedicine. What's new in miniaturizing? | Laurent Levy has a deep understanding of the technical, scientific, intellectual property and marketing issues associated with nanotechnologies, because he has been working-and achieving- in these areas for more than a decade (...) |
 | Michael Lutz General Manager of Cogenics,Epidauros WORKSHOP5:Theranostics | Dr. Michael Lutz came to Clinical Data Inc., a NASDAQ listed biotech company in August 2007 following the acquisition of Epidauros where he served as Chief Executive Officer since April 2006.(...) |
 | Ramkumar Mandalam, Ph.D. President and CEO Cellerant Therapeutics Inc WORKSHOP 6: Cellular therapies, challenging but promising | Ramkumar Mandalam, Ph.D. is President and CEO of Cellerant Therapeutics Inc, a biotechnology company developing cellbased drugs and antibodies for oncology applications and blood-related disorders. |
 | Paolo Mangiagalli BD Medical PANEL 2 :The brain device interface | Paolo Mangiagalli recently joined Becton Dickinson as Advanced Technology Manager for the Pharmaceutical System business unit. (...) |
 | Dr Dominique Masset AFSSAPS WORKSHOP4: New trends in Nanomedicine. What's new in miniaturizing? | Dominique Masset is a Pharm D Toxicologist and has experience in clinical Toxicology and drug safety development. He is currently the Head of the Department of Toxicology at the French Agency for the Safety of Health Products (Ministry of Health). (...) |
 | Prof. Ariel Miller Head of The Center for Multiple Sclerosis & Brain Research at Carmel Medical Center Technion-Israel Institute of Technology WORKSHOP5: Theranostics | Prof. Ariel Miller holds a M.D. degree from the “Sackler” school of Medicine, Tel-Aviv, and a Ph.D. degree in Experimental Sciences (Neurobiology) from the Hebrew University of Jerusalem. He is a senior neurologist since 1989. (...) |
.jpg) | Marie-Laure Muiras Project Director, ACIES WORKSHOP1:Overview of the public financial supports of biotech | Marie-Laure MUIRAS gained her PhD in molecular biology in 1997 from the University Pierre et Marie Curie (Paris, France). In 2005, she completed an Executive MBA at Durham Business School (Durham, UK) ( ...) |
.jpg) | Philippe Pouletty Chairman of France Biotech,Founder and General Partner of Truffle Capital PANEL1: More R&D investment but no more drugs approved. What's wrong? | MD, 50, is Founder and General Partner of Truffle Capital, a leading venture fund based in Paris, and Chairman of France Biotech, the French biotechnology association (...) |
 | Steen Riisgaard Chairman for EuropaBio, CEO Novozymes A/S, Denmark OPENING PLENARY SESSION | Steen Riisgaard is President & CEO of Novozymes A/S and has had the position since Novozymes A/S was demerged from Novo Nordisk A/S in 2000(...) |
 | Peter Rosholm Vice President, Novozymes WORKSHOP3:The Cleantech Market in Europe | Novozymes Biopharma, part of Novozymes a world leader in bioinnovation, is a specialist in recombinant protein production for the biopharmaceutical industry, specializing in microbial expression technology. |
 | Gilles Rubinstenn CEO, Fondation Pierre-Gilles de Gennes PANEL 2 :The brain device interface | Holding a PhD from the University Pierre and Marie Curie on organic chemistry and statistical quantum mechanics (1996), alumnus of the Ecole Normale Supérieure of Paris (1994), Gilles Rubinstenn began his career in 1998 at L'Oréal (...) |
| Dr. Leonide Saad Vice President,Proteus Venture Partners WORKSHOP 6 Cellular therapies, challenging but promising | Leonide Saad brings several years of experience to the field of Regenerative Medicine. With experience encompassing fundamental and clinical research as well as regulatory work, Dr. Saad has nearly worked across the entire R&D chain of Regenerative Medicine. (...) |
 | Richard Seabrook Head of Business Development Technology Transfer, Wellcome Trust PANEL1: More R&D investment but no more drugs approved. What's wrong? | Richard Seabrook PhD, MBA, is a founding member of the Technology Transfer Division, Wellcome Trust, where he is Head of Business Development. |
.jpg) | Michael Siani-Rose President and Founder of Theregen, Inc., WORKSHOP 6Cellular therapies, challenging but promising | Michael Siani-Rose, President and Founder of Theregen, Inc., has more than 15 years of biotechnology experience. He has extensive expertise in the computational chemistry and drug discovery fields, and has held managerial and scientific positions at Protos/Chiron Corporation, Kosan Biosciences and Affymetrix ( ...) |
.jpg) | Mondher Toumi President and Founder of Creativ-Ceutical PANEL2 :The brain device interface | Mondher Toumi is President and Founder of Creativ-Ceutical and Professor at Lyon I Université, department of decision sciences and health policies where he is head of the Chair of market access. His field of expertise is business development, licensing, M&A, market access, pricing and reimbursement and competitive intelligence. |
 | Prof. Marcella Trombetta Chairman Laboratories of Chemistry & Biomaterials, CIR-Center of Integrated Research,University Campus Bio-Medico of Rome WORKSHOP4: New trends in Nanomedicine. What's new in miniaturizing? | Marcella Trombetta is born the 1st november 1967 and she is Full Professor of Chemical Fundamentals in Technology at the University Campus Bio-Medico of Rome.(...) |
 | Daniel Vasmant Head of the Health, Biotechnology and Food Industry department,General Directorate for Competitiveness, Enterprise and Services of the French ministry of Economy, Industry and employment WORKSHOP1:Overview of the public financial supports of biotech | Daniel VASMANT is heading the Health, Biotechnology and Food Industry department within General Directorate for Competitiveness, Enterprise and Services of the French ministry of the French Ministry of Economy, Industry and employment |
 | Barend Verachtert Head of sector - SME - policy issues, Directorate General Research, European Commission WORKSHOP1:Overview of the public financial supports of biotech | Barend Verachtert is the head of sector for the development of SME research policies and the promotion of SME participation in the 7th Framework Programme for Research and Development of the European Commission (FP7). (...) |
 | Elias A. Zerhouni Director, U.S. National Institutes of Health OPENING PLENARY SESSION | Elias A. Zerhouni, M.D. was the 15th Director of the National Institutes of Health. From May 2002 to October 2008 he oversaw the NIH’s 27 Institutes and Centers with more than 18,000 employees and a fiscal year 2008 budget of $29.5 billion. He successfully led a series of reforms at the NIH that led to the passing of the NIH reform Act of 2006 by the US Congress. |
Previous
top